$495.97 Million in Sales Expected for MEDNAX, Inc. (NYSE:MD) This Quarter

Wall Street brokerages expect MEDNAX, Inc. (NYSE:MDGet Rating) to post $495.97 million in sales for the current fiscal quarter, Zacks reports. Six analysts have made estimates for MEDNAX’s earnings, with the highest sales estimate coming in at $503.51 million and the lowest estimate coming in at $488.20 million. MEDNAX reported sales of $472.96 million in the same quarter last year, which indicates a positive year-over-year growth rate of 4.9%. The company is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that MEDNAX will report full-year sales of $2.01 billion for the current financial year, with estimates ranging from $1.99 billion to $2.03 billion. For the next fiscal year, analysts expect that the business will post sales of $2.13 billion, with estimates ranging from $2.04 billion to $2.16 billion. Zacks’ sales averages are an average based on a survey of research firms that follow MEDNAX.

MEDNAX (NYSE:MDGet Rating) last released its earnings results on Thursday, April 28th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm had revenue of $482.20 million during the quarter, compared to analysts’ expectations of $471.29 million. MEDNAX had a net margin of 4.73% and a return on equity of 15.64%. MEDNAX’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.20 EPS.

A number of equities analysts have weighed in on MD shares. TheStreet lowered shares of MEDNAX from a “b-” rating to a “c+” rating in a report on Wednesday, April 13th. StockNews.com lowered shares of MEDNAX from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. Zacks Investment Research lowered shares of MEDNAX from a “buy” rating to a “hold” rating and set a $25.00 price target on the stock. in a report on Wednesday, April 20th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of MEDNAX from $24.00 to $16.00 in a report on Tuesday. Finally, Credit Suisse Group decreased their price target on shares of MEDNAX from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Wednesday, February 23rd. Eight research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $27.25.

Several large investors have recently bought and sold shares of the stock. O Shaughnessy Asset Management LLC lifted its holdings in MEDNAX by 5,380.0% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 1,096 shares of the company’s stock worth $31,000 after buying an additional 1,076 shares in the last quarter. Prospera Financial Services Inc acquired a new position in MEDNAX in the 1st quarter worth $49,000. Point72 Hong Kong Ltd acquired a new position in MEDNAX in the 4th quarter worth $57,000. Meeder Asset Management Inc. lifted its holdings in MEDNAX by 1,246.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,127 shares of the company’s stock worth $60,000 after buying an additional 1,969 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in MEDNAX by 120.2% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 3,107 shares of the company’s stock worth $85,000 after buying an additional 1,696 shares in the last quarter. Institutional investors and hedge funds own 95.68% of the company’s stock.

MD stock traded up $0.69 during midday trading on Monday, hitting $18.38. The stock had a trading volume of 2,269,413 shares, compared to its average volume of 632,714. The firm has a market cap of $1.60 billion, a PE ratio of 17.18, a price-to-earnings-growth ratio of 1.08 and a beta of 2.05. The company’s 50-day moving average price is $22.23 and its 200 day moving average price is $24.56. MEDNAX has a 12-month low of $17.17 and a 12-month high of $35.67. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.63 and a quick ratio of 1.63.

MEDNAX Company Profile (Get Rating)

MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Read More

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.